(NASDAQ:NVAX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant ...

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

The stock's fall snapped a five-day winning streak.

Investors are weighing Nvidia's big AI plans and puzzling over Trump's tariff policy in the wait for fresh jobs data.

Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in ...

Investors speculated on Covid vaccine firms. Despite the seasonal strength for flu-related vaccines ending, Moderna (MRNA) ...